The prevalence of SHPT (PTH>300 pg/mL) in the entire European dialysis population ranges from 30% to 49%, with 54% in Americans and 10%–30% in Asians.[4, 6, 8, 37] Furthermore, high serum PTH levels and abnormal calcium homeostasis have been reported to increase the risk of cardiovascular disease and fractures in patients,[38, 39] seriously endangering patients’ quality of life and survival. The gene discussed is PTH; the disease is cardiovascular disorder.